In the subgroup analysis of three clinical studies [43–45], the CR rates of venetoclax-based drug regimen in R/R AML patients with IDH mutations were 1/11, 2/12 and 3/5, respectively, but the sample size of these studies was very small. The gene discussed is IDH1; the disease is acute myeloid leukemia.